GeoVax to Present Promising Immune Response Data for GEO-CM04S1 in CLL Patients at EHA 2025 Congress
TL;DR
GeoVax Labs' GEO-CM04S1 vaccine shows superior immune response in CLL patients, offering a competitive edge in immunocompromised populations underserved by current COVID-19 vaccines.
GEO-CM04S1 utilizes a synthetic MVA vector to express SARS-CoV-2 S and N antigens, aiming for broader and more durable immune protection in Phase 2 trials.
GeoVax's innovative vaccine could significantly improve COVID-19 protection for immunocompromised individuals, marking a step forward in global health equity and patient care.
Discover how GeoVax's GEO-CM04S1 vaccine, with its unique MVA platform, is redefining COVID-19 protection for those with chronic lymphocytic leukemia and beyond.
Found this article helpful?
Share it with your network and spread the knowledge!
GeoVax Labs, Inc., a clinical-stage biotechnology company, is set to present significant findings from its Phase II randomized clinical trial at the European Hematology Association (EHA) 2025 Hybrid Congress. The study highlights the enhanced cellular immune response of GEO-CM04S1, a next-generation COVID-19 vaccine, in patients with Chronic Lymphocytic Leukemia (CLL), a group known for their compromised immune responses to vaccines.
The presentation, led by Dr. Alexey V. Danilov, will detail how GEO-CM04S1, developed using GeoVax's MVA multi-antigen platform, outperforms authorized mRNA-based COVID-19 vaccines in eliciting immune responses in CLL patients. This development is crucial as it addresses the unmet need for effective vaccination strategies in immunocompromised individuals, particularly those with hematologic malignancies who are at higher risk of severe COVID-19 outcomes.
GEO-CM04S1's design, which includes both spike and nucleocapsid antigens of SARS-CoV-2, aims to offer broader and more durable protection. The upcoming presentation at EHA 2025 underscores the vaccine's potential to fill a critical gap in current vaccination efforts, especially for vulnerable populations. Dr. Kelly T. McKee, Jr., GeoVax's Chief Medical Officer, emphasized the importance of these findings in meeting the real-world needs of patients with hematologic malignancies.
Curated from NewMediaWire
